LITTLE GREEN PHARMA LIMITED (LGP)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

LGP - LITTLE GREEN PHARMA LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences

Year End: June

GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences

Debt/EBITDA: -0.55

Index:

LAST PRICE	CHANGE +/-	CHANGE %	VOLUME
$0.115 09 May 2025	0.000 OPEN $0.12	0.000 HIGH $0.12	67,957 LOW $0.12

OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . DXB . EOF . GSS . HXL . IDT . IMM . IMU . IVX . MAP . MSB . MVP . MYX . NEU . NUZ . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .

FNARENA'S MARKET CONSENSUS FORECASTS

- No Record -

HISTORICAL DATA ARE ALL IN AUD

Copyright © 2025 FactSet UK Limited. All rights reserved

Title	2018	2019	2020	2022	2023	2024
EPS Basic	xxx	xxx	xxx	xxx	xxx	-2.7
DPS All	xxx	xxx	xxx	xxx	xxx	0.0
Sales/Revenue	xxx	xxx	xxx	xxx	xxx	25.6 M
Book Value Per Share	xxx	xxx	xxx	xxx	xxx	25.7
Net Operating Cash Flow	xxx	xxx	xxx	xxx	xxx	0.1 M
Net Profit Margin	xxx	xxx	xxx	xxx	xxx	-31.81 %

EPS Basic

Negative
Growth
Slowing

DPS All

Negative
Growth
Slowing

Sales/Revenue

Negative
Growth
Slowing

Book Value Per Share

Negative
Growth
Slowing

Net Operating Cash Flow

Negative
Growth
Slowing

Net Profit Margin

Negative
Growth
Slowing

Title	2018	2019	2020	2022	2023	2024
Return on Capital Employed	xxx	xxx	xxx	xxx	xxx	-10.22 %
Return on Invested Capital	xxx	xxx	xxx	xxx	xxx	-9.75 %
Return on Assets	xxx	xxx	xxx	xxx	xxx	-8.82 %
Return on Equity	xxx	xxx	xxx	xxx	xxx	-10.22 %
Return on Total Capital	xxx	xxx	xxx	xxx	xxx	-14.04 %
Free Cash Flow ex dividends	xxx	xxx	xxx	xxx	xxx	-0.6 M

Return on Capital Employed

Negative
Growth
Slowing

Return on Invested Capital

Negative
Growth
Slowing

Return on Assets

Negative
Growth
Slowing

Return on Equity

Negative
Growth
Slowing

Return on Total Capital

Negative
Growth
Slowing

Free Cash Flow ex dividends

Negative
Growth
Slowing

Title	2018	2019	2020	2022	2023	2024
Short-Term Debt	xxx	xxx	xxx	xxx	xxx	3 M
Long Term Debt	xxx	xxx	xxx	xxx	xxx	3 M
Total Debt	xxx	xxx	xxx	xxx	xxx	5 M
Goodwill - Gross	xxx	xxx	xxx	xxx	xxx	-
Cash & Equivalents - Generic	xxx	xxx	xxx	xxx	xxx	5 M
Price To Book Value	xxx	xxx	xxx	xxx	xxx	0.54

Short-Term Debt

Negative
Growth
Slowing

Long Term Debt

Negative
Growth
Slowing

Total Debt

Negative
Growth
Slowing

Goodwill - Gross

Cash & Equivalents - Generic

Negative
Growth
Slowing

Price To Book Value

Negative
Growth
Slowing

Title	2018	2019	2020	2022	2023	2024
Capex	xxx	xxx	xxx	xxx	xxx	1.4 M
Capex % of Sales	xxx	xxx	xxx	xxx	xxx	5.63 %
Cost of Goods Sold	xxx	xxx	xxx	xxx	xxx	16 M
Selling, General & Admin. Exp & Other	xxx	xxx	xxx	xxx	xxx	22 M
Research & Development	xxx	xxx	xxx	xxx	xxx	6 M
Investments - Total	xxx	xxx	xxx	xxx	xxx	0 M

Capex

Negative
Growth
Slowing

Capex % of Sales

Negative
Growth
Slowing

Cost of Goods Sold

Negative
Growth
Slowing

Selling, General & Admin. Exp & Other

Negative
Growth
Slowing

Research & Development

Negative
Growth
Slowing

Investments - Total

Negative
Growth
Slowing

Negative

Growth

Slowing

EXPERT VIEWS
EXTRA COVERAGE

EXPERT VIEWS

Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

BROKER	DATE	RATING	RECOMMENDATION	TARGET PRICE	% TO REACH TARGET	COMMENTARY
No data available in table

Access Stockbroker Research History >

EXTRA COVERAGE

Display All Commentary

No. Of Recommendations

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER	DATE	RATING	RECOMMENDATION	TARGET PRICE	% TO REACH TARGET	COMMENTARY
Canaccord Genuity	07/05/2025	1	Speculative Buy	$0.18	56.52%	Canaccord Genuity lowers its price target for Little Green Pharma to $0.18 from $0.21 while retaining a Speculative Buy rating. The analyst explains March quarter result met expectations, though gross profit margins declined for a third consecutive quarter to 33%, leading to trimmed earnings (EBITDA) forecasts to $0.6m from $0.9m, and FY26 to $3.9m from $4.5m. The broker's net income estimated for FY26 is reduced to $0.8m from $1.5m. Revenue forecast for FY25 is maintained at $36.6m, up 40% year-on-year, with March revenue at a stronger-than-expected $4.0m, indicating a favourable run rate for FY26. The broker flags the need for careful working capital management given a cash balance of $2.4m. European growth remains a key driver, with March quarter sales in that region rising 50%. FORECAST Canaccord Genuity forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -0.90 cents. Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 0.30 cents.

BROKER

DATE

RATING

RECOMMENDATION

TARGET PRICE

% TO REACH TARGET

COMMENTARY

Canaccord Genuity

07/05/2025

Speculative Buy

$0.18

56.52%

Canaccord Genuity lowers its price target for Little Green Pharma to $0.18 from $0.21 while retaining a Speculative Buy rating.

The analyst explains March quarter result met expectations, though gross profit margins declined for a third consecutive quarter to 33%, leading to trimmed earnings (EBITDA) forecasts to $0.6m from $0.9m, and FY26 to $3.9m from $4.5m.

The broker's net income estimated for FY26 is reduced to $0.8m from $1.5m.

Revenue forecast for FY25 is maintained at $36.6m, up 40% year-on-year, with March revenue at a stronger-than-expected $4.0m, indicating a favourable run rate for FY26.

The broker flags the need for careful working capital management given a cash balance of $2.4m. European growth remains a key driver, with March quarter sales in that region rising 50%.

FORECAST
Canaccord Genuity forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -0.90 cents.
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 0.30 cents.

Access Extra Coverage Research History >

LGP STOCK CHART

FNArena News on LGP

1	Australian Broker Call Extra Edition – May 08, 2025 May 08 2025 - Daily Market Reports

2	Australian Broker Call Extra Edition – Apr 07, 2025 Apr 07 2025 - Daily Market Reports

3	In Case You Missed It – BC Extra Upgrades & Downgrades – 25-10-24 Oct 25 2024 - Weekly Reports

4	In Brief: Aurum, Hillgrove & Little Green Pharma Oct 25 2024 - Weekly Reports

5	Australian Broker Call Extra Edition – Oct 24, 2024 Oct 24 2024 - Daily Market Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1	Rudi’s View: CSL & NextDC May 08 2025 - Rudi's View

2	Behring Margin Outlook Still Main Game For CSL Feb 13 2025 - Australia

3	Dr Boreham’s Crucible: Arovella Therapeutics Aug 29 2024 - Small Caps

4	ResMed’s Margin Upside Excites Aug 07 2024 - Australia

5	Dr Boreham’s Crucible: Aroa Biosurgery Jul 29 2024 - Small Caps

6	CSL Shares Breaking Free Jul 23 2024 - Technicals

7	Dr Boreham’s Crucible: SDI Jul 19 2024 - Small Caps

8	‘Defensive’ Pharmaceutical Wholesalers In Focus Jul 18 2024 - Australia

9	Twists And Turns Of Telix And Australian Biotech Jul 10 2024 - Small Caps

10	Dr Boreham’s Crucible: Radiopharm Theranostics Jul 03 2024 - Small Caps

1	Australian Broker Call Extra Edition – May 08, 2025 May 08 2025 - Daily Market Reports

2	Australian Broker Call Extra Edition – Apr 07, 2025 Apr 07 2025 - Daily Market Reports

3	In Case You Missed It – BC Extra Upgrades & Downgrades – 25-10-24 Oct 25 2024 - Weekly Reports

4	In Brief: Aurum, Hillgrove & Little Green Pharma Oct 25 2024 - Weekly Reports

5	Australian Broker Call Extra Edition – Oct 24, 2024 Oct 24 2024 - Daily Market Reports

Get 2 Weeks free trial

Sign Up

Member Login

LITTLE GREEN PHARMA LIMITED (LGP)
Share Price Analysis and Chart